BioSpace News Archive

Drug Development

OPKO Health Announces Topline Results from Phase 2 Trial Evaluating RAYALDEE to Treat Symptomatic COVID-19 Outpatients

OPKO Health, Inc. (NASDAQ: OPK) announces preliminary topline results from its Phase 2 trial with RAYALDEE ® to treat mild-to-moderate COVID-19.

December 23, 2021
·
5 min read
iCAD to Participate at the 11th Annual LifeSci Partners Virtual Corporate Access Event

iCAD, Inc. today announced that it will attend the 11th Annual LifeSci Partners Corporate Access Event, being held virtually from January 5th to 7th , 2022.

December 23, 2021
·
1 min read
Pharm Country

Vallon Pharmaceuticals Announces Achievement of Last Patient Last Visit in Pivotal SEAL Study for Lead Program, ADAIR

Vallon Pharmaceuticals, Inc. today announced that the last patient has completed their final visit in the pivotal SEAL intranasal abuse study evaluating ADAIR1.

December 23, 2021
·
4 min read
Genetown

CENTOGENE Wins Award in Digital Healthcare Innovation for Artificial Intelligence (AI) Platform Leading Biomarker Discovery

Centogene N.V. today announced that it has been awarded the Health-i Award, which recognizes companies that are transforming healthcare in Germany and beyond.

December 23, 2021
·
5 min read
Drug Development

Newly published results showed spesolimab significantly improved signs and symptoms of flares in rare, life-threatening skin disease, generalized pustular psoriasis

Boehringer Ingelheim announced today the publication in The New England Journal of Medicine of new data from the pivotal Phase II Effisayil™ 1 trial.

December 23, 2021
·
6 min read
BioCapital

Healis Therapeutics announces mission to deliver new class of neuromuscular treatments in psychiatry

Healis Therapeutics , a privately held biotechnology company, today announces its mission to deliver a new class of neuromuscular therapeutics in psychiatry.

December 23, 2021
·
1 min read
BioForest

Lumen Bioscience Releases Data on Potent, Orally Delivered Biologic Drug Cocktail for Preventing C. difficile Infection

Lumen also announces successful Cohort 1 results in Phase 1 clinical trial.

December 23, 2021
·
6 min read
Drug Development

DESTINY-Lung04 Phase 3 Trial of ENHERTU® Initiated in Patients with Previously Untreated HER2 Mutant Metastatic Non-Small Cell Lung Cancer

DESTINY-Lung04 Phase 3 Trial of ENHERTU ® Initiated in Patients with Previously Untreated HER2 Mutant Metastatic Non-Small Cell Lung Cancer.

December 23, 2021
·
21 min read
Job Trends

Horizon Therapeutics plc to Participate in Upcoming Investor Conferences - Dec 23, 2021

Horizon Therapeutics plc announced that the Company will participate in the following upcoming virtual investor conferences.

December 23, 2021
·
2 min read
Pharm Country

Patritumab Deruxtecan Granted U.S. FDA Breakthrough Therapy Designation in Patients with Metastatic EGFR-Mutated Non-Small Cell Lung Cancer

Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) to patritumab deruxtecan (HER3-DXd).

December 23, 2021
·
9 min read